6th Annual Platelet Colloquium Print

6th Annual Platelet Colloquium
 

January 13-15, 2011
Willard InterContinental Hotel
Washington, DC


Overarching Themes

The overarching theme for the Platelet Colloquium’s 6th annual program is the translation of fundamental scientific concepts underlying circulatory and device-associated vascular injury to the management of patients receiving cardiac device therapy. A bench-to-bedside forum will feature basic science insights dedicated to platelet receptor activation, inflammatory cell biology, endothelial dysregulation, and the effects of biomechanical stress on coagulation and hemostatic proteins. These constructs will collectively be translated, in the context of prior and ongoing clinical trials, to better determine the pathobiology and overall incidence of adverse events and their attenuation, modulation and prevention through findings derived from the investigation of patients receiving cardiac devices.


Objectives

Objective 1: To gain a better understanding of the role of platelets in the response to cardiovascular device-associated injury.

Objective 2: To describe the relationship between mechanical cardiac devices, shear stress and alterations in platelet biology and function.

Objective 3: To review existing evidence derived from in vitro, in vivo, and clinical investigations supporting therapies to modify platelet- associated responses to device-related injury.

Agenda

Thursday, January 13, 2011

7:00 – 9:00 pm
Evening Reception and Dinner
The Nest Lounge
Mezzanine Level

Friday, January 14, 2011

7:00 – 7:45 am
Breakfast Buchanan Room
Lower Level

7:45 am – 5:00 pm
Meeting Pierce Room
Lower Level

7:45 – 8:00 am
Introduction
Richard C. Becker, MD
Duke University Medical Center, Durham, NC

Session I: Platelets, Inflammation and the Response to Device-Mediated Cardiac Injury

8:00 – 8:20 am Platelet - Leukocyte - Vessel Wall Interactions
Guy Zimmerman, MD
University of Utah School of Medicine, Salt Lake City, UT

8:20 – 8:35 am
Discussion

8:35 – 8:55 am
Coronary Shear Stress and Platelet Activation; Models and Mechanisms
Lisa K. Jennings, PhD
University of Tennessee, Memphis, TN

8:55 – 9:10 am
Discussion

9:10 – 9:30 am
The Platelet Proteome and Transcriptome in Vascular Responses
Jane E. Freeman, MD
Boston University School of Medicine, Boston, MA

9:30 – 9:45 am
Discussion

9:45 – 10:10 am
Break

10:10 – 10:30 am
Bare Metal and Drug-Eluting Coronary Stents: Histopathological Insights into Acute and Delayed Healing Responses
Aloke Finn, MD
Emory Clinic, Atlanta, GA

10:30 – 10:45 am
Discussion

Session II: Noncoronary Injury, Platelet Response, and Coagulation Effects

10:45 – 11:05 am
Left Ventricular Assist Devices and Acquired Von Willebrand Disease
Richard C. Becker, MD
Duke University School of Medicine, Durham, NC

11:05 – 11:20 am
Discussion

11:20 – 11:40 am
Prosthetic Cardiac Valves: Effects on Platelet Biology
Daniel A. Bluestein, MD
State University of New York at Stony Brook, Stony Brook, NY

11:40 – 11:55 am
Discussion

11:55 am – 12:15 pm
General Discussion

12:15 – 1:30 pm
Lunch and Break Buchanan Room
Lower Level

Session III: Modifying Platelet-Mediated Responses to Device Injury

1:30 – 1:45 pm
Assessing Platelet Activation: In Vivo and In Vitro Models
Peter L. Gross, MD, MSc
McMaster University, Hamilton, ON, Canada

1:45 – 2:00 pm
Discussion

2:00 – 2:20 pm
P2Y12 Antagonism: GRAVITAS and the Future of Point-of-Care Testing
Matthew J. Price, MD
Scripps Clinic, La Jolla, CA

2:20 – 2:35 pm
Discussion

2:35 – 2:55 pm Can Novel Polymer and Stent Design Modify the Platelet-Mediated Response to Injury?
Juan Granada, MD
Columbia University, New York, NY

2:55 – 3:10 pm Discussion

3:10 – 3:30 pm Break

3:30 – 4:00 pm
Platelet Antagonists as Modulators of Response to Injury
Steven R. Steinhubl, MD
Geisinger Medical Center, Danville, PA

4:00 – 4:15 pm Discussion

4:15 – 4:35 pm Prasugrel, Ticagrelor, Cangrelor, Elinogrel: Have We Shifted the Thrombosis-to-Bleeding Ratio in the Right Direction?
Christopher P. Cannon, MD
Harvard Medical School, Boston, MA

4:35 – 4:50 pm
Discussion

4:50 – 5:00 pm
General Discussion

5:00 pm Break for Day

6:30 – 9:00 pm
Reception and Dinner TBD

Saturday, January 15, 2011

7:00 – 8:00 am
Breakfast Buchanan Room
Lower Level

8:00 – 11:00 am
Meeting Pierce Room
Lower Level
Session IV: Modulating Platelet-Mediated Responses to Injury: Phase 2/3 Clinical Trials

8:00 – 8:20 am
Early Career Investigator Award

8:20 – 8:35 am
Discussion

8:35 – 9:05 am
The FDA Label: Defining the Black-Box and Interaction Warnings for Platelet Inhibition after Coronary Stenting
Andrew Farb, MD
U.S. Food and Drug Administration, Bethesda, MD

9:05 – 9:20 am
Discussion

9:20 – 9:40 am
Dual Antiplatelet Therapy for the Long-Term Prevention of Stent Thrombosis: Insights from Clinical Registries
Harold L. Dauerman, MD
University of Vermont, Burlington, VT

9:40 – 9:55 am
Discussion

9:55 – 10:15 am
Dual Antiplatelet Therapies for Long-Term Prevention of Stent Thrombosis: When Will We Have a Trial-Based Answer?
Donald Cutlip, MD
Harvard Medical School, Boston, MA

10:15 – 10:30 am
Discussion

10:30 – 10:50 am Future Research Directions: Moving the Field Forward
Group

10:50 – 11:00 am Summary and Closing Remarks
Susan S. Smyth, MD, PhD
University of Kentucky College of Medicine, Lexington, KY

11:00 am
Departures